D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Tuesday morning,Benzinga reports. They currently have a $32.00 price objective on the stock.

CMPX has been the topic of a number of other research reports. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $2.92 on Tuesday. Compass Therapeutics has a 12 month low of $0.76 and a 12 month high of $4.08. The firm has a market capitalization of $401.76 million, a PE ratio of -7.89 and a beta of 1.17. The business’s fifty day moving average price is $2.56 and its 200 day moving average price is $1.93.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, equities analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Rovin Capital UT ADV acquired a new stake in shares of Compass Therapeutics during the third quarter worth about $25,000. Tower Research Capital LLC TRC raised its stake in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after acquiring an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics during the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at approximately $27,000. Finally, Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.